Bayer and Evotec Join Forces to Develop Treatment for Cardiovascular Diseases
Shots:
- Bayer and Evotec have shifted the aim of their strategic agreement to develop precision therapeutics for addressing cardiovascular diseases (CVDs)
- The partnership will employ Evotec's disease modeling abilities leveraging human induced pluripotent stem cells (iPSCs) to identify and validate targets for cardiovascular diseases
- Under the collaboration, both Bayer & Evotec will provide drug targets & advanced technology platforms to develop candidates. They will jointly handle pre-clinical development, with Bayer taking responsibility for clinical development & commercialization. Financial terms were undisclosed
Ref: Bayer | Image: Bayer
Related News:- Dewpoint Therapeutics Collaborates with Evotec to Accelerate its Oncology Pipeline
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
